Recepteerkunde pp 813-855 | Cite as

35 Parenteraal

  • Yvonne Bouwman-Boer
  • Andra´s Vermes

Samenvatting

Parenterale toedieningsvormen zijn steriele preparaten die in het lichaam worden geïnjecteerd of op andere wijze in weefsels worden gebracht. Tot deze categorie horen injecties en infusievloeistoffen, maar ook parenterale voeding. Vaak kiezen we een parenterale vorm omdat orale toediening niet mogelijk is, of om een snel effect te krijgen. Gereguleerde afgifte is parenteraal echter ook mogelijk.

35.12 Literatuur

  1. 1.
    Duyvendak M, Bouwman-Boer Y, Kooij YMAW van, et al. Het probleem van de farmacotherapeutische onderbouwing. Pharm Weekbl 2003;138(20):708–12.Google Scholar
  2. 2.
    European Pharmacopoeia, 6de ed. Straatsburg: Council of Europe, 2008, Parenteral Preparations (Parenteralia) 01/2008:052–0.Google Scholar
  3. 3.
    Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 5de ed. Lippincott Williams & amp; Wilkins. 2006:473 (micellen); 619 (liposomen).Google Scholar
  4. 4.
    Latorre F de, Nolan J, Robertson C et al. European Resuscitation Council Guidelines 2000 for Adult Advanced Life Support. Resuscitation 48 (2001):211–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Zuidema J, Pieters FAJM, Duchateau GSMJE. Release and absorption rate of intramuscularly injected pharmaceuticals. Int J Pharm 1988;47:1–12.CrossRefGoogle Scholar
  6. 6.
    Kadir F, Zuidema J, Pijpers A, et al. Drug lipophilicity and release pattern of some beta-blocking agents after intra-adipose injection in pigs. Int J Pharm 1990;64:171–80.CrossRefGoogle Scholar
  7. 7.
    SmPC Eligard, via www.cbg-meb.nl, geraadpleegd maart 2009.Google Scholar
  8. 8.
    Akers MJ, Nail SL, Saffell-Clemmer W. Top ten hot topics in parenteral science and technology. PDA J Pharm Sci Techn 2007;61(5): 337–61.Google Scholar
  9. 9.
    WIP Richtlijn Ziekenhuizen Intravasale therapie 2006. Te raadplegen op www.wip.nl.
  10. 10.
    Steffens KJ. Parenterale Therapie und Fremdpartikeln. 1 Mitt: Die Bedeutung partikulärer Verunreinigung bei der parenteralen Therapie. Pharm Ind 1989;51:799–806.Google Scholar
  11. 11.
    Haloperidol, in: Bracher F, Heisig P, Langguth P et al. Kommentar zur Europäisches Arzneibuch. Wissenschaftl Verlagsges/GOVI-Verlag, Stuttgart/Frankfurt. 1999.Google Scholar
  12. 12.
    Yalkowski SH, Valvani SC. Precipitation of solubilized drugs due to injection or dilution. Drug Intell Clin Pharm 1977;11:417–9.Google Scholar
  13. 13.
    Narazaki R, Sanghvi R, Yalkowsky SH. Estimation of drug precipitation upon dilution of pH-cosolvent solubilized formulations. Chem Pharm Bull 2007;55(8):1203–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Oldenhof HGJ. Fenytoïnetoediening per infuus: zijn er verschillen tussen Muldis en het FNA-injectiepreparaat. Ziekenhuisfarmacie 1998;4:89–94.Google Scholar
  15. 15.
    Weerd G de, Meer YG van der. Bereiding en houdbaarheid van een co-trimoxazol infuus. Ziekenhuisfarmacie 8-1992:1–8.Google Scholar
  16. 16.
    Mottu F, Laurent A, Rüfenacht DA et al. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J Pharm Sci Techn 2000;54(6):456–69.Google Scholar
  17. 17.
    Grouls RJE, Korsten EHM, Yaksch TL. General considerations in the formulation of drugs for spinal delivery. In: Yaksch TL ed. Spinal drug delivery. Elsevier 1999. ISBN 0-444-82901-6: 37–5.Google Scholar
  18. 18.
    Visudyne<Superscript>®</Superscript>. EPAR, Scientific Discussion via www.emea.europa.eu. Geraadpleegd mei 2009.
  19. 19.
    Visudyne<Superscript>®</Superscript>. SmPC, via http://eudrapharm.eu/eudrapharm. Geraadpleegd mei 2009.Google Scholar
  20. 20.
    Polyoxyethylene Castor Oil Derivatives. Rowe, Sheskey PJ, Weller PJ. Handbook of Pharmaceutical Excipients 4de ed. Pharmaceutical Press en Am Pharm Assoc, Bath, 2003:474–7.Google Scholar
  21. 21.
    Prograft<Superscript>®</Superscript> SmPC 10 april 2009, via www.cbg-meb.nl. Geraadpleegd mei 2009.
  22. 22.
    Prograf<Superscript>®</Superscript> 2006. Labeltext Drugs@fda: via http://www.accessdata.fda.gov.Google Scholar
  23. 23.
    Clarke's Analysis of Drugs and Poisons Ed 3 vol 2. Pharmaceutical Press, Londen, Chicago:1598.Google Scholar
  24. 24.
    Stranz M. Adjusting pH and osmolarity levels to fit standards and practices. The diverse and conflicting standards and practices in infusion therapy. J Vascular Access Devices 2002(Fall):12–9.Google Scholar
  25. 25.
    Dipyridamolum. Ph. Eur. 01/2005:119–9.Google Scholar
  26. 26.
    Dipyridamolum. Bracher F, Heisig P, Langguth P et al. Kommentar zur Europäisches Arzneibuch. Wissenschaftl Verlagsges/GOVI-Verlag, Stuttgart/Frankfurt. 30.Lfg 2008.Google Scholar
  27. 27.
    Persantin, SmPC 2004, via cbg-meb.nl. Geraadpleegd mei 2009.Google Scholar
  28. 28.
    Dijkstra J, Dekker D. High-performance liquid chromatographic determination of phosphate esters of dexamethasone and prednisolone and their sulphite adducts. J Chromatogr 1982;238:4–7.CrossRefGoogle Scholar
  29. 29.
    Trose D, Slowig P. Zur Stabilisierung von Physostigminsalicylat-Injektionslösungen. Pharmazie 1985:40:124–6.PubMedGoogle Scholar
  30. 30.
    Trose D, Kässmann A. Zur Stabilisierung von Physostigminsalicylat-Injektionslösungen. 2. Mitteilung. Pharmazie 1990;45:783–5.PubMedGoogle Scholar
  31. 31.
    Hussain A, Wahner H, Triplett J. Unusual Reversible Attack by Sodium Bisulfite on Physostigmine. J Pharm Sci 1978;67:742–3.PubMedGoogle Scholar
  32. 32.
    Hussain A, Iga K. Kinetics and Equilibria of the Reaction between Physostigmine and Bisulfite. J. Parent. Drug Ass 1979;33:32–9.Google Scholar
  33. 33.
    Yang ST, Wilken LO. The effects of withdrawal and duration of storage on the sterility of multiple dose vials. J. Parenter Sci Technol 1987;41:105–9.PubMedGoogle Scholar
  34. 34.
    Thonke M, Hildebrandt R, Dressel H. Über den Keimgehalt angebrochener Insulin-Mehrdosenbehälter. Pharmazie 1990;45:785–6.PubMedGoogle Scholar
  35. 35.
    Note for Guidance on inclusion of antioxidants and antimicrobial preservatives in medicinal products, 8 juli 1997. Te raadplegen op: www.emea.europa.eu.
  36. 36.
    Huyghe I van, Nimme P van, Lammens G, et al. Antimicrobial preservatives in oily preparations. Pharmeuropa 2003;15(2):266–70.Google Scholar
  37. 37.
    CPMP/QWP directive 159/96 January 1998. Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution. Te raadplegen op: www.emea.europa.eu.
  38. 38.
    Intravenous Nursing Society. Revised intravenous nursing standards of practice. (1998). Journal of Intravenous Nursing (Supplement), Vol. 21, No. 15. S3–11.Google Scholar
  39. 39.
    Lafeber HN, Zoeren-Grobben D van, van Beek RHT et al. Werkboek enterale en parenterale voeding bij pasgeborenen. 2de druk 2004. ISBN 90 5383 927 5. 39a: 65; 39b: 67; 39c: 140; 39d: 138; 39e: 13–9.Google Scholar
  40. 40.
    Erixon M, Wieslander A, Lindén T et al. How to avoid glucose degradation products in peritoneal dialysis fluids. Peritoneal Dialysis International 2006;26:490–7.PubMedGoogle Scholar
  41. 41.
    Knapp JZ, Barber TA, Lieberman A. Sources of particulate matter in pharmaceutical and medical products. In: Liquid- and surface-borne particle measurement handbook. New York: Marcel Dekker 1996;637–60.Google Scholar
  42. 42.
    Kraus J. Zuurstof verwijderen met argon. Ziekenhuisfarmacie 1996;12(1):48–9.Google Scholar
  43. 43.
    Conemans JMH, Bos JM, Duchateau AMJA. De bereiding van combinaties van een lokaal anaestheticum en epinefrine. Ziekenhuisfarmacie 1993;9:94–7.Google Scholar
  44. 44.
    Swart CW, Smeets OSNM, Le Brun PPH. Zuurstof meten en verwijderen bij parenterale apotheekbereidingen. Meer stabiliteit door minder oxidatie. Pharm Weekbl 2004;139(37):1207–10.Google Scholar
  45. 45.
    Ph Eur 6de ed. 2.9.17: Test for extractable volume of parenteral preparations.Google Scholar
  46. 46.
    Pharmaceutical dosage forms. Injections. & lt;1151 & gt;, USP 32;2009:66–7.Google Scholar
  47. 47.
    Sielaff G. Wagner P. Ampullendichtigkeitsprüfung - Grenzen des Farbbadverfahrens. Pharm Ind 1980;42:1190–4.Google Scholar
  48. 48.
    Ph Eur 6.0 5.1.1 Methods of preparation of sterile products. 01/2008:5010–1.Google Scholar
  49. 49.
    Sotacor. SmPC juli 2003, via www.cbg-meb.nl. Geraadpleegd november 2007.
  50. 50.
    Bosker HA, Dijkman PRM van. Leidraad Cardiologie 2002. Mediselect bv.Google Scholar
  51. 51.
    Newton DW. Drug incompatibility chemistry. Am J Health Syst Pharm 2009;66:348–57.CrossRefPubMedGoogle Scholar
  52. 52.
    Trissel L. Handbook on injectable drugs. Am Soc Health-System Pharm. Geldende editie.Google Scholar
  53. 53.
    Bing C. Extended stability for parenteral drugs. Am Soc Health-System Pharm. Geldende editie.Google Scholar
  54. 54.
    Soest-Segers van, Cheung, K. Let op! Pharm Weekbl 2009;17 april:18–9.Google Scholar
  55. 55.
    Monografieën Cytostatica. Slotervaart ziekenhuis. Te raadplegen op: www.slotervaartziekenhuis.nl/apotheek.
  56. 56.
    Richtlijn Voor Toediening Gereed Maken (VTGM) van parenteralia op verpleegafdelingen in ziekenhuizen. Versie 2. 1, 5 februari 2009. Te raadplegen op: www.nvza.nl.
  57. 57.
    Parshuram CS et al. Occurence and impact of unanticipated variation in intravenous methotrexate dosing. Ann Pharmacother 2006;40:805–11.PubMedGoogle Scholar
  58. 58.
    Parshuram CS et al. Discrepancies between ordered and delivered concentrations of opiate infusions in critical care. Crit Care Med 2003;31:2483–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Sauerwein HP, Romijn JA, Soeters PB. Kunstmatige voeding bij door ziekte veranderde stofwisseling. Elsevier/Bunge. Maarssen. 1999.Google Scholar
  60. 60.
    Wipkink-Bakker A, Heuvel E van den, Strebe E. Voeding buiten alles om. Elsevier/De Tijdstroom Maarssen, RET Leiden. 1999.Google Scholar
  61. 61.
    Koletzko B, Goulet O, Hunt J et al. Parenteral Nutrition Guidelines Working Group. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr. 2005 Nov;41 Suppl 2:S1–87.Google Scholar
  62. 62.
    Burnham WR, Hansrani PK, Knott CE et al. Stability of a fat emulsion based intravenous feeding mixture. Int J Pharm 1983;13:9–22.Google Scholar
  63. 63.
    Schrøder AM. Total parenteral nutrition - problems in compatibility and stability. Eur J Hospital Pharmacy Practice 2008;14(1):65–7.Google Scholar
  64. 64.
    FDA Safety Alert. Hazards of precipitation associated with parenteral nutrition. April 18, 1994. Via: http://www.fda.gov. Geraadpleegd mei 2009.
  65. 65.
    Ball PA. Methods of assessing stability of parenteral nutrition regimens. Curr Opin Clin Nutr Metab Care. 2001;5:345–9.Google Scholar
  66. 66.
    Koster VS, Kuks PFM, Lange R et al. Particle size in parenteral fat emulsions; what are the true limitations? Int J Pharm 1996;134:235–8.CrossRefGoogle Scholar
  67. 67.
    Driscoll DF. Stability and compatibility assessment techniques for total parenteral nutrition admixtures: setting the bar according to pharmacopeial standards. Curr Opn Clin Nutr Metab Care 2005;8:297–303.Google Scholar
  68. 68.
    Driscoll DF. Lipid Injectable Emulsions: Pharmacopeial and Safety Issues. Pharm Res 2006;23:1959–69.CrossRefPubMedGoogle Scholar
  69. 69.
    Driscoll DF, Silvestri AP, Bistrian BR et al. Stability of total nutrient admixtures with lipid injectable emulsions in glass versus plastic packaging. Am J Health-Syst Pharm 2007;64:396–403.Google Scholar
  70. 70.
    & lt;729 & gt; Globule Size Distribution In Lipid Injectable Emulsions. In: USP, 31ste ed., Rockville, 2008.Google Scholar
  71. 71.
    Timmer JG, Schipper HG. Peripheral venous nutrition: the equal relevance of volume load and osmolarity in relation to phlebitis. Clin Nutr 1991;10(2):71–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Conemans JMH, Hanff LM, Maas AJJ et al. Omgaan met infusieapparatuur; beleid, toepassing en beheer. NVKF, Utrecht.1999.Google Scholar
  73. 73.
    Beslismodel, draagbare infuuspompen TNO/UMC. Juni, 2005. Ook te raadplegen op www.infuustechnologie.nl.Google Scholar
  74. 74.
    Wille JC. De plaats van infuusfilters bij de preventie van flebitiden. ZIP 1989;5:139–42.Google Scholar
  75. 75.
    Branje J. Infuusregelaars geregeld. Pharm Weekbl 2000;135:218–9.Google Scholar
  76. 76.
    KNMP-Kennisbank patiëntenvoorlichting/diabeteshulpm/insulinepompen. Geraadpleegd mei 2009.Google Scholar
  77. 77.
    Risicoprofiel Infusietechnologie. Te bestellen via www.tno.nl/VeiligeOK.
  78. 78.
    The AccessAbility(tm) Programme. www.accessability-by-bard.co.uk.Google Scholar
  79. 79.
    Geavanceerde medische technologie in de thuissituatie - Inventarisatie, gebruikersaantallen en risico's. IGZ februari 2009.Google Scholar
  80. 80.
    Boom FA. In-line filtratie. Ziekenhuisfarmacie 1991;7:46–8.Google Scholar

Copyright information

© Bohn Stafleu van Loghum, onderdeel van Springer Uitgeverij 2009

Authors and Affiliations

  • Yvonne Bouwman-Boer
  • Andra´s Vermes

There are no affiliations available

Personalised recommendations